[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"RespirAI US Inc\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":36},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":25,"lastUpdatePostDateStruct":26,"startDateStruct":29,"completionDateStruct":31,"leadSponsor":33,"locationsCount":5},"100635566",false,"NCT07554352","Early Detection of COPD Exacerbations Using Home Monitoring Device","A Multi-center, Observational Prospective Clinical Study to Evaluate the Safety and Effectiveness of a Home - Monitoring COPD Management Software for Early Detection of Exacerbations.","Inclusion Criteria:\n\n* Age \\>21 years.\n* Physician-diagnosed COPD at least 6 months prior to screening visit.\n* Two or more moderate COPD exacerbations in the past 6 months or 1 severe exacerbation during the past 6 months.\n* Free of exacerbation for 1 month before enrollment.\n\nExclusion Criteria:\n\n* Unable or willing to sign an informed consent.\n* Unable to complete the 6-minute walk test due to physical or mental health conditions.\n* Patients with cardiac pacemaker, defibrillators, or other implanted electronic devices.\n* Pregnancy\n* Study clinician determines that the patient is unable or unwilling to comply with all study procedures.","ALL","21 Years",{"count":18,"type":19},30,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to evaluate the safety and effectiveness of a home-monitoring device (RespirAI) in the early detection of COPD exacerbations in adults (age \\>21) with physician-diagnosed COPD who are at high risk for exacerbations. The study will collect data from participants with COPD that will be analyzed using an AI-based algorithm to predict exacerbation events. The device's predictions will then be compared against clinically documented exacerbations to assess detection accuracy.",[23],"COPD Exacerbation","NOT_YET_RECRUITING","2026-04-21",{"date":27,"type":28},"2026-04-28","ACTUAL",{"date":30,"type":19},"2026-05",{"date":32,"type":19},"2027-05",{"name":34,"class":35},"RespirAI US Inc","INDUSTRY",""]